Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML. Neijssen J, et al. Among authors: schuurman j. J Biol Chem. 2021 Jan-Jun;296:100641. doi: 10.1016/j.jbc.2021.100641. Epub 2021 Apr 8. J Biol Chem. 2021. PMID: 33839159 Free PMC article.
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.
van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW. van der Neut Kolfschoten M, et al. Among authors: schuurman j. Science. 2007 Sep 14;317(5844):1554-7. doi: 10.1126/science.1144603. Science. 2007. PMID: 17872445
A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.
Rider DA, Havenith CE, de Ridder R, Schuurman J, Favre C, Cooper JC, Walker S, Baadsgaard O, Marschner S, vandeWinkel JG, Cambier J, Parren PW, Alexander DR. Rider DA, et al. Among authors: schuurman j. Cancer Res. 2007 Oct 15;67(20):9945-53. doi: 10.1158/0008-5472.CAN-07-1148. Cancer Res. 2007. PMID: 17942927 Clinical Trial.
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.
Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Labrijn AF, et al. Among authors: schuurman j. Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20. Nat Biotechnol. 2009. PMID: 19620983
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.
Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, Aalberse RC, Heck AJ, van de Winkel JG, Schuurman J, Parren PW. Labrijn AF, et al. Among authors: schuurman j. J Immunol. 2011 Sep 15;187(6):3238-46. doi: 10.4049/jimmunol.1003336. Epub 2011 Aug 12. J Immunol. 2011. PMID: 21841137
112 results